Our Technology

Transformative

With our novel D-Domain technology, based on a synthetic binding scaffold, our goal is to advance cell therapies by enhancing safety, efficacy, and access.

Proprietary Platforms

The D-Domain

Core Technology

The D-Domain is a small, stable, fully synthetic binding protein with a hydrophobic core.

Its small size, when used as a chimeric antigen receptor, potentially allows for high transduction efficiency, resulting in high cell surface expression of the D-Domain based CAR Ts (ddCAR).

The unique structure and properties of the D-Domain allow us to generate diverse libraries of proprietary, target-binding domains with improved specificity and enhanced binding affinity. The D-Domain serves as the foundation of our proprietary ddCAR and ARC-SparX platforms.

Learn more about this technology in our overview video.

ddCAR

Engineered T cells expressing D-Domain based CARs that target a specific antigen on diseased cells.

ddcar
ddCar
ddCAR is a single-infusion CAR-T that utilizes Arcellx's novel D-Domain in lieu of the traditional scFv antigen recognition motif
ddCAR
Upon engagement with the antigen on a target cell, the ddCAR activates the T cell to kill the target cell
ddCAR
Our first ddCAR is anitocabtagene autoleucel, a therapy targeting the BCMA antigen, which is under clinical evaluation for relapsed or refractory multiple myeloma in a phase 1 study
ddCar
ddCAR is a single-infusion CAR-T that utilizes Arcellx's novel D-Domain in lieu of the traditional scFv antigen recognition motif
ddCAR
Upon engagement with the antigen on a target cell, the ddCAR activates the T cell to kill the target cell
ddCAR
Our first ddCAR is anitocabtagene autoleucel, a therapy targeting the BCMA antigen, which is under clinical evaluation for relapsed or refractory multiple myeloma in a phase 1 study

Learn more about our uniquely controllable cell therapies that we’re developing for the treatment of cancer and autoimmune diseases.

ARC-SparX

Dosable, controllable, and adaptable, this platform combines Arcellx’s universal ARC-T and specialized SparX proteins to bind to and kill targeted disease cells.

arcsparx
ARCSparx
Since ARC-T cells are universal, more than one type of SparX protein can potentially be given simultaneously, which may address antigen loss or heterogeneity of diseased cells and improve efficacy of therapy
ARCSparx
SparX proteins are composed of antigen-binding D-Domain(s) that bind to specific diseased cells and a tag, which is a unique binding domain that is designed to be recognized only by ARC-T cells
ARCSparx
ARC-T cells are ddCARs designed to recognize the unique binding domain in a SparX protein
ARCSparx
ARC-T cells are inactivated until they bind to a SparX protein bound to a diseased cell, making T cell killing functions controllable and dependent on the dose of SparX protein, which could allow for improved T cell associated toxicity and lead to enhanced safety
ARCSparx
ARC-T cells are ddCARs designed to recognize the unique binding domain in a SparX protein
ARCSparx
SparX proteins are composed of antigen-binding D-Domain(s) that bind to specific diseased cells and a tag, which is a unique binding domain that is designed to be recognized only by ARC-T cells
ARCSparx
ARC-T cells are inactivated until they bind to a SparX protein bound to a diseased cell, making T cell killing functions controllable and dependent on the dose of SparX protein, which could allow for improved T cell associated toxicity and lead to enhanced safety
ARCSparx
Since ARC-T cells are universal, more than one type of SparX protein can potentially be given simultaneously, which may address antigen loss or heterogeneity of diseased cells and improve efficacy of therapy

Partnering

We are relentlessly driven to pursuing a cure with every cell of our being. We are looking for partners who share that conviction. If you would like to learn more about partnering with Arcellx, please contact the business development group at [email protected].
Press Releases
Presentations